melanoma - Daily Scope 24

Merck stock jumps 13%: MRK hits records on Keytruda + cancer vaccine Phase 3 win

August 19, 2026 by Daily Scope 24

Merck stock: burgundy-cream capsule merging into green candlestick chart on teal dashboard background

Merck stock rose about 13% on Aug. 19 after intismeran autogene plus Keytruda met Phase 3 melanoma endpoints with Moderna. MRK closed near $152, above stale analyst targets. Keytruda was half of Q2 revenue.

Moderna stock: Phase 3 melanoma win with Merck — the numbers are not out yet

August 19, 2026 by Daily Scope 24

Moderna stock: lime DNA helix on indigo, magenta-gold rising candlestick chart, screen-print grain

Aug. 19: Moderna and Merck said intismeran autogene plus Keytruda met Phase 3 melanoma endpoints. MRNA ripped on the headline; MRK rose too. Hazard ratios not disclosed — full data at a medical meeting.